HealthX Ventures hires from portfolio company Redox
HealthX Ventures has hired Redox Engine's business development staffer.
Valeant to pay down debt with $2.12B in asset sales
Valeant was the talk of the town (or at least Union Square) on day two of the J.P. Morgan Healthcare Conference, announcing two divestitures worth $2.12 billion and unveiling a plan to pay down $5 billion in debt over the next 18 months.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Vinod Khosla: The healthcare startups I hate…
During J.P. Morgan week, Vinod Khosla stops by StartUp Health Festival to discuss entrepreneurship, what works in healthcare and the kind of startups he would never work with.
7 insider tricks GE Ventures uses to scale its portfolio companies
Only one in 500 new businesses in the United States will reach at least $100 million in revenue, and only one in 17,000 will see $500 million in revenue.
Oncobiologics: The most interesting biotech at #JPM17?
Oncobiologics has no home ground advantage. There is no clearly defined path with the FDA, EMA or any other regulatory agency. And it’s battling against the largest biotech and pharma companies in the world as they work to extend their patent exclusivity. How can it survive and bring biosimilars to the market at 50% of the cost?
Two charts capture the dark mood around Big Pharma in 2017
At a breakfast reception during the ongoing J.P. Morgan Healthcare Conference, the mood around the prospects for Big Pharma in 2017 was downright gloomy.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
What’s the biggest challenge for life science software developers? Keeping up with pace of change
Roger Pellegrini, who handles marketing at Benchling, talked about the company's motivation for improving the effectiveness of its drug development software at Rock Health's reception during the J.P. Morgan Healthcare conference this week.
Many healthcare technologies are married to the fee-for-service model
Healthcare companies are looking to integrate technology into their platforms as they prepare for a new era of value-based care. The problem? Those technologies, workflows, processes and providers are all built with the fee-for-service model in mind, said the digital health panelists at the J.P. Morgan Healthcare Conference.
Joe Biden: What the hell are we doing?
In San Francisco during J.P. Morgan week, the vice president called for the end to a siloed healthcare system to help accelerate the battle against cancer and announced what he will do after his tenure in public office ends.
Deals roundup: Optum acquires surgical group, Aledade lands $20M
UnitedHealthGroup's OptumCare subsidiary is acquiring Surgical Care Affiliates for $2.3 billion, Takeda is ponying up $5.2 billion to acquire Ariad Pharmaceuticals, while Aledade closed on a $20 million funding round.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Toby Cosgrove: How Cleveland Clinic felt the urgency for same-day appointments
The CEO of Cleveland Clinic talked about the one case that led to the decision to ask every patient who called in whether they want to see a doctor that same day.
Recycling drugs: Roivant’s subsidiary model powers on
Roivant's search for overlooked and underpriced compounds continues, as it builds out more subsidiaries and completes enrollment on its first Phase 3 trial.
SnapMD CEO: This will be a tipping point year for telemedicine (Updated)
SnapMD's priorities for the funding injection are to bolster the company’s sales and marketing efforts and leverage its channel partner program to boost revenue.
Calling early stage healthcare and life science startups for INVEST Pitch Perfect competition
Are you an early stage healthcare or life science startup in search of investors? MedCity INVEST's Pitch Perfect competition offers a chance to shine a spotlight on your business to an audience of investors. The deadline for applications is January 31.
Illumina & IBM Watson form cancer genomics partnership
IBM Watson Health and Illumina have formed their very own dream team for tumor sequencing, curation and interpretation. Combined, the two platforms help make cancer genomics more accessible and scalable, but it's the potential for greater scientific standardization that the field needs most.